Lignin-graft-PLGA drug-delivery system improves efficacy of MEK1/2 inhibitors in triple-negative breast cancer cell line

被引：20
|
作者：
Byrne, C. Ethan [1 ]
Astete, Carlos E. [1 ]
Vaithiyanathan, Manibarathi [2 ]
Melvin, Adam T. [2 ]
Moradipour, Mahsa [3 ]
Rankin, Stephen E. [3 ]
Knutson, Barbara L. [3 ]
Sabliov, Cristina M. [1 ]
Martin, Elizabeth C. [1 ]
机构：
[1] Louisiana State Univ, Dept Biol & Agr Engn, Baton Rouge, LA 70803 USA
[2] Louisiana State Univ, Cain Dept Chem Engn, Baton Rouge, LA 70803 USA
[3] Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA
来源：
NANOMEDICINE | 2020年 / 15卷 / 10期
基金：
美国国家科学基金会; 美国食品与农业研究所;
关键词：
breast cancer; drug delivery; lignin; nanoparticle; targeted therapies; triple-negative; QUARTZ-CRYSTAL MICROBALANCE; SUPPORTED LIPID-BILAYERS; POLYMERIC NANOPARTICLES; QCM-D; RAS ONCOGENES; MUTANT KRAS; CHEMOTHERAPY; MODEL; RESISTANCE; MEMBRANES;
D O I：
10.2217/nnm-2020-0010
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
Aim: Few targeted therapies are available for triple-negative breast cancer (TNBC) patients. Here, we propose a novel alkaline-lignin-conjugated-poly(lactic-co-glycolic acid) (L-PLGA) nanoparticle drug delivery system to improve the efficacy of targeted therapies. Materials & methods: L-PLGA nanoparticles (NPs) loaded with the MEK1/2 inhibitor GDC-0623 were characterized, tested in vitro on MDA-MB-231 TNBC cell line and compared with loaded PLGA NPs. Results: Loaded L-PLGA NPs were less than half the size of PLGA NPs, had slower drug release and improved the efficacy of GDC-0623 when tested in vitro. We demonstrated that GDC-0623 reversed epithelial-to-mesenchymal transition in TNBC. Conclusion: Our findings indicate that L-PLGA NPs are superior to PLGA NPs in delivering GDC-0623 to cancer cells for improved efficacy in vitro. Graphical abstract
引用
收藏
页码：981 / 1000
页数：20
相关论文
共 36 条
  • [1] Dual inhibition of MEK1/2 and MEK5 suppresses the EMT/migration axis in triple-negative breast cancer through FRA-1 regulation
    Hoang, Van T.
    Matossian, Margarite D.
    La, Jacqueline
    Hoang, Kristine
    Ucar, Deniz A.
    Elliott, Steven
    Burks, Hope E.
    Wright, Thomas D.
    Patel, Saloni
    Bhatt, Akshita
    Phamduy, Theresa
    Chrisey, Douglas
    Buechlein, Aaron
    Rusch, Douglas B.
    Nephew, Kenneth P.
    Anbalagan, Murali
    Rowan, Brian
    Cavanaugh, Jane E.
    Flaherty, Patrick T.
    Miele, Lucio
    Collins-Burow, Bridgette M.
    Burow, Matthew E.
    JOURNAL OF CELLULAR BIOCHEMISTRY, 2021, 122 (08) : 835 - 850
  • [2] Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer
    Lee, Jangsoon
    Lim, Bora
    Pearson, Troy
    Choi, Kuicheon
    Fuson, Jon A.
    Bartholomeusz, Chandra
    Paradiso, Linda J.
    Myers, Thomas
    Tripathy, Debu
    Ueno, Naoto T.
    BREAST CANCER RESEARCH AND TREATMENT, 2019, 175 (02) : 339 - 351
  • [3] Cancer Cell Membrane Wrapped Nanoparticles for the Delivery of a Bcl-2 Inhibitor to Triple-Negative Breast Cancer
    Scully, Mackenzie A. A.
    Wilkins, Dana E. E.
    Dang, Megan N. N.
    Hoover, Elise C. C.
    Aboeleneen, Sara B. B.
    Day, Emily S. S.
    MOLECULAR PHARMACEUTICS, 2023, 20 (08) : 3895 - 3913
  • [4] Targeting BCL-xL improves the efficacy of bromodomain and extra-terminal protein inhibitors in triple-negative breast cancer by eliciting the death of senescent cells
    Gayle, Sylvia S.
    Sahni, Jennifer M.
    Webb, Bryan M.
    Weber-Bonk, Kristen L.
    Shively, Melyssa S.
    Spina, Raffaella
    Bar, Eli E.
    Summers, Mathew K.
    Keri, Ruth A.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2019, 294 (03) : 875 - 886
  • [5] Current situation of programmed cell death protein 1/programmed cell death ligand 1 inhibitors in advanced triple-negative breast cancer
    Liang, Yuehua
    Liu, Xiaoran
    Li, Kun
    Li, Huiping
    CHINESE JOURNAL OF CANCER RESEARCH, 2022, 34 (02) : 117 - 130
  • [6] Development of a phosphoaminopyrazine-loaded cellulose nanoparticle drug delivery system for targeted treatment of triple-negative breast cancer
    Mohammadpanah, Fahimeh
    Behrooz, Rabi
    Pooyan, Mahsa
    Gholivand, Khodayar
    Roohzadeh, Roohollah
    INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 2025, 300
  • [7] Layer-by-Layer Nanoparticles of Tamoxifen and Resveratrol for Dual Drug Delivery System and Potential Triple-Negative Breast Cancer Treatment
    Al-jubori, Ali A.
    Sulaiman, Ghassan M.
    Tawfeeq, Amer T.
    Mohammed, Hamdoon A.
    Khan, Riaz A.
    Mohammed, Salman A. A.
    PHARMACEUTICS, 2021, 13 (07)
  • [8] Isolation and Establishment of a Highly Proliferative, Cancer Stem Cell-Like, and Naturally Immortalized Triple-Negative Breast Cancer Cell Line, KAIMRC2
    Ali, Rizwan
    Al Zahrani, Hajar
    Barhoumi, Tlili
    Alhallaj, Alshaimaa
    Mashhour, Abdullah
    Alshammari, Musaad A.
    Alshawakir, Yasser A.
    Baz, Omar
    Alanazi, Abdullah H.
    Khan, Abdul Latif
    Al Nikhli, Hassan
    Al Balwi, Mohammed A.
    Al Riyees, Lolwah
    Boudjelal, Mohamed
    CELLS, 2021, 10 (06)
  • [9] Efficacy and safety of PD-1 and PD-L1 inhibitors combined with chemotherapy in randomized clinical trials among triple-negative breast cancer
    Qi, Yihang
    Zhang, Wenxiang
    Jiang, Ray
    Xu, Olivia
    Kong, Xiangyi
    Zhang, Lin
    Fang, Yi
    Wang, Jingping
    Wang, Jing
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [10] Efficacy and safety profiles of programmed cell death-1/programmed cell death ligand-1 inhibitors in the treatment of triple-negative breast cancer: A comprehensive systematic review
    Lazarus, Gilbert
    Audrey, Jessica
    Iskandar, Anthony William Brian
    ONCOLOGY REVIEWS, 2019, 13 (02) : 161 - 169
1234